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Abstract Suramin, a hexasulfonated naphthylurea, is known to
induce differentiation and inhibit proliferation, angiogenesis, and
development of tumors. It has also been shown to suppress the
activity of the protein kinase C (PKC) isoenzymes K, L, and Q.
Here we report on a differential effect of suramin on PKCW and
various PKC isoforms representing the cPKC, nPKC, and aPKC
group of the PKC family. In the absence of any cofactors
suramin activates all PKC isoforms in the order of aPKC-
jEPKCWs cPKC, nPKCN. As judged by the Vmax/KM ratios
(0.5 for PKCW and 2.2 for PKCj) the substrate syntide 2 is
phosphorylated by suramin-activated PKCj around four times
more effectively than by suramin-activated PKCW. Suramin-
activated PKCW behaves like that activated by phosphatidylser-
ine and the phorbol ester TPA regarding autophosphorylation
and differential inhibition by the PKC inhibitors Goº 6976 and Goº
6983. In the presence of activating cofactors, such as phospha-
tidylserine and TPA or cholesterol sulfate (for PKCj), the
activity of the aPKCj is further stimulated, PKCW is not
significantly affected, and the cPKCs and the nPKCN are
strongly inhibited by suramin. The differential action of suramin
on PKC isoenzymes might play a role in some of its biological
effects, as for instance inhibition of proliferation and tumor
development. Moreover, due to this property suramin will
possibly be a valuable tool for discriminating the activities of
PKC isoenzymes in vitro and in vivo.
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1. Introduction
Suramin is a hexasulfonated naphthylurea possessing a
broad spectrum of biological and therapeutic properties (for
reviews see [1,2]). It has been used in the treatment of sleeping
sickness and other parasitic diseases for 70 years [3]. More
recently, suramin has been shown to inhibit the reverse tran-
scriptase of several animal retroviruses [4], including that of
HIV-1 [5], and was clinically tested in patients with AIDS [6],
but was found to be too toxic in vivo [7]. Furthermore, sur-
amin displayed antitumor activity toward several metastatic
cancers, such as prostatic carcinoma (for a review see [1]).
Suramin has multiple modes of action. It inhibits angiogenesis
[9] and proliferation [1,10], induces di¡erentiation [11], inter-
feres with the recognition of several growth factors by their
membrane receptors [12,13], forms complexes with a large
variety of plasma proteins, most importantly albumin [14],
and inhibits a great number of cellular, parasitic, and retro-
viral enzymes [3^5,8,15^22], including protein kinase C (PKC;
[11,23]).
The isoenzymes of the PKC family play a major role in
signal transduction pathways a¡ecting proliferation, di¡eren-
tiation, and tumor development (for reviews see [24,25]). In
this context the ability of suramin to inhibit PKC is of great
interest. As yet, just the conventional PKCs K, L, Q were
investigated in this respect [23]. The PKC family, however,
consists of at least 11 phospholipid-dependent isoenzymes
(for reviews see [24,25]). In addition to the Ca2-dependent
and diacylglycerol- or 12-O-tetradecanoylphorbol-13-acetate
(TPA)-activated cPKC group (K, L1, L2, Q), we presently
know the Ca2-independent, diacylglycerol- (or TPA)-acti-
vated nPKC group (N, O, R, a) and the Ca2-independent,
diacylglycerol- (or TPA)-unresponsive aPKC group (j, S/V).
Recently, a novel PKC isoenzyme was discovered that was
termed PKCW [26]. Like the nPKCs, PKCW is Ca2-independ-
ent and activated by diacylglycerol (or TPA), but signi¢cantly
di¡ers in some structural and enzymatic features from the
other PKC isotypes [26^34]. Therefore, PKCW might be clas-
si¢ed as a member of a novel subgroup of the PKC family.
Here we show that suramin di¡erentially a¡ects various
PKC isoenzymes. Whereas the activated forms of cPKCs
and the nPKCN are inhibited by suramin, the activity of the
aPKCj is further stimulated and that of PKCW not signi¢-
cantly changed. This di¡erential action on the activity of PKC
isoenzymes might be crucial for some biological e¡ects of
suramin, such as its antiproliferative and antineoplastic activ-
ity. Moreover, suramin promises to be a valuable tool to dis-
criminate the activities of PKC isoforms in vitro and possibly
also in vivo.
2. Materials and methods
2.1. Materials
12-O-tetradecanolyphorbol-13-acetate (TPA) was supplied by Dr.
E. Hecker, German Cancer Research Center (Heidelberg, Germany).
Goº 6976 and Goº 6983 were kindly provided by Goºdecke A.G. (Frei-
burg, Germany). Syntide 2 and the Ser-pseudosubstrate peptide N
were synthesized by Dr. R. Pipkorn, German Cancer Research Center
(Heidelberg, Germany). Other materials were bought from companies
as indicated: Suramin, Alexis (Gruºnberg, Germany); cholesterol sul-
fate (CS) and phosphatidylserine (PS), Sigma (Munich, Germany);
[Q-32P]ATP (speci¢c activity, 5000 Ci/mmol), Hartmann Analytic
(Braunschweig, Germany).
2.2. Recombinant PKCW and PKCj from baculovirus-infected insect
cells
Sf9 or Sf158 cells were infected with the recombinant baculovirus,
cell extracts were prepared and used as a source for PKCW or PKCj,
as described previously [28,30,35].
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2.3. Puri¢ed cPKC and PKCN
Puri¢cation of cPKC (a mixture of PKCK, PKCL, PKCQ) from
mouse brain and PKCN from porcine spleen was performed as de-
scribed elsewhere [36,37].
2.4. Protein kinase assay
Phosphorylation reactions were carried out in a total volume of
100 Wl containing bu¡er (50 mM Tris-HCl, pH 7.5, 10 mM L-mer-
captoethanol), 4 mM MgCl2, 5 Wl of a cell extract containing the
recombinant kinase or 4 mU (based on the phosphorylation of his-
tone III-S) of puri¢ed cPKC or PKCN, 35 WM ATP containing 1 WCi
[Q-32P]ATP and 5 Wg of syntide 2 as substrate. Suramin, PS, TPA, CS,
Goº 6976 and Goº 6983 were added at concentrations indicated in the
legends of the ¢gures. After incubation for 7 min at 30‡C, the reaction
was terminated by transferring 50 Wl of the assay mixture onto a
20 mm square piece of phosphocellulose paper (Whatman p81), which
was washed 3 times in deionized water and twice in acetone. The
radioactivity on each paper was determined by liquid scintillation
counting. Phosphate incorporated into the substrate peptide was ob-
tained by subtracting values determined in the absence of the kinase.
2.5. Autophosphorylation
Autophosphorylation was carried out essentially as described for
the protein kinase assay. However, no substrate was added and the
assay contained 7 WCi [Q-32P]ATP. Proteins of the reaction mixture
were separated by SDS polyacrylamide gel electrophoresis and visual-
ized by autoradiography.
3. Results and discussion
3.1. Activation of PKC isoenzymes by suramin
Suramin was found to be an activator of PKC isoenzymes
in the absence of any cofactor. Di¡erential activation of PKC
isoforms was observed, when the activation by suramin was
compared with that by the classical PKC activators PS and
TPA or, in the case of the atypical PKCj, with that by CS
(Fig. 1). At a concentration of 10 WM, suramin was four times
more e¡ective than 20 WM CS in activating PKCj for phos-
phorylation of syntide 2. In our hands, CS was the most
e⁄cient activator of the TPA-unresponsive PKCj known at
that time. We found that 20 WM CS increased the activity of
PKCj by 170% (data not shown) as compared to 60% as
reported by Denning et al. [38]. Phosphorylation of other
substrates, such as the Ser-pseudosubstrate peptide N, by
PKCj were also stimulated by CS and suramin (data not
shown). Activation of PKCW by 10 or 100 WM suramin and
activation by PS/TPA were about equally e¡ective. On the
other hand, cPKC from mouse brain (a mixture of PKCK,
PKCL, PKCQ) and the nPKCN were barely activated by sur-
amin (maximally 35% of the activation by PS/TPA). Previ-
ously it was reported, however, that in the presence of calcium
suramin was able to activate cPKCs very e¡ectively [23]. The
authors suggested that suramin might act as a negatively
charged phospholipid analog and therefore, together with cal-
cium, activates cPKCs. As PKCW, PKCN, and PKCj are in-
dependent of calcium, activation of these isoenzymes by such
a mechanism is not conceivable. Thus, suramin is a novel and
e¡ective activator of PKCW and especially of PKCj. PKCW
activated by suramin (1, 10, or 100 WM) phosphorylated syn-
tide 2 with a KM of 10.9 WM (Fig. 2a). Vmax increased with the
suramin concentration from 1.3 pmol phosphate/min (1 WM
suramin) to 5.9 pmol/min (100 WM suramin). With 10 WM
suramin almost maximal activation of PKCW was reached
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Fig. 1. Activation of various PKC isoforms by suramin. PKC activ-
ities were determined by the protein kinase assay in the absence of
any cofactor and with syntide 2 as substrate, as described in Section
2. Suramin was added at the concentrations indicated in the ¢gure.
PKC activities are given as per cent of the activity of the PS/TPA-
(cPKC, PKCW, PKCN) or CS- (PKCj) stimulated kinase (100%).
Values are the means ( þ S.E.) of two independent experiments.
Fig. 2. Lineweaver-Burk plots of suramin-activated phosphorylation of syntide 2 by PKCW (a) and PKCj (b). Phosphorylation of syntide 2 at
various concentrations was performed as described in Fig. 1. The intercepts of the double-reciprocal plots with the x-axis give the KM and those
with the y-axis the Vmax values. PKCW : KM = 10.9 WM, Vmax = 1.3 pmol/min (1 WM suramin).
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(Vmax : 5.3 pmol/min). KM and Vmax values of syntide 2 phos-
phorylation by PKCj that was maximally activated by 10 WM
suramin (see Fig. 1) were 68.1 WM and 150.2 pmol phosphate/
min, respectively (Fig. 2b). As judged by the Vmax/KM ratio of
0.5 for PKCW and 2.2 for PKCj (with 10 WM suramin each),
syntide 2 was phosphorylated by suramin-activated PKCj
around four times more e⁄ciently than by suramin-activated
PKCW. This is in agreement with the results shown in Fig. 1.
Previously we reported on a very potent activation of PKCW
by heparin and dextran sulfate which, like suramin, are poly-
anions [32]. Based on these and some other results we sug-
gested that polyanions possibly brake up the interaction of an
autoinhibitory basic domain with an acidic domain in the
inactive form of PKCW and that the e⁄cacy of activation
depends on the structure of these negatively charged com-
pounds. In preliminary experiments we could show that hep-
arin and dextran sulfate increase also the activity of PKCj.
Thus PKCj might be activated by polyanions in a similar way
as PKCW. In contrast to heparin and dextran sulfate, however,
suramin is a much more potent activator of PKCj than of
PKCW.
3.2. Autophosphorylation and inhibition by PKC inhibitors of
suramin-activated PKCW
Autophosphorylation of PKCW was also clearly stimulated
by suramin (Fig. 3). Suramin (10 WM) alone, i.e. in the ab-
sence of any other cofactor, was similarly active as PS/TPA in
increasing autophosphorylation of PKCW. Autophosphoryla-
tion of PKCj turned out to be strong in the absence of any
cofactor and could not be increased signi¢cantly by addition
of CS or suramin. Therefore, data on the autophosphoryla-
tion of PKCj are not shown.
Suramin-induced PKCW activity was suppressed by the
PKC inhibitors Goº 6976 and Goº 6983 in a similar way
(Fig. 4) as PS/TPA-induced PKCW activity (see [30]). The
IC50 values of Goº 6976 and Goº 6983, as estimated from
Fig. 4, were 7 nM and 7 WM, respectively. In the nM range,
the indolocarbazole Goº 6976 had previously been shown to
inhibit preferentially cPKC isotypes [39,40] and PKCW [30],
and the bisindolylmaleimide Goº 6983 to suppress all PKCs
except PKCW [30].
3.3. E¡ect of suramin on activated PKCs
Suramin has been reported to inhibit the activated cPKCs
K, L, and Q [23], whereas the e¡ects on other PKC isoforms
have not yet been investigated. In agreement with the earlier
report [23], we found PS/TPA-activated cPKC puri¢ed from
mouse brain (a mixture of PKCK, PKCL, PKCQ) to be inhib-
ited by suramin with an IC50 of around 50 WM. In addition we
could show that PS/TPA-activated PKCN was also inhibited
by suramin with a similar IC50, whereas PS/TPA-activated
PKCW was not inhibited, but rather slightly stimulated by
suramin (Fig. 5). CS-activated PKCj was even signi¢cantly
stimulated by 10 WM suramin (more than 200%, Fig. 5). At
higher concentrations (100 and 200 WM) suramin was less
potent in stimulating PKCj, probably due to a concomitant
inhibitory action on the kinase activity.
Thus, suramin allows for a di¡erentiation of PKC isoen-
zymes by acting di¡erentially on the activated isoforms. Due
to this property, suramin might become a valuable tool for the
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Fig. 3. E¡ect of suramin on the autophosphorylation of PKCW. Au-
tophosphorylation of recombinant PKCW (5 Wl of cell extract) was
performed as described in Section 2. The kinase was phosphorylated
in the absence of any cofactor (^), in the presence of suramin
(SUR) and 10 Wg PS/100 nM TPA (PS/TPA). Phosphorylated pro-
teins were separated by SDS polyacrylamide gel electrophoresis
(7.5%) and visualized by autoradiography. The molecular mass (116
kDa) of a standard protein is indicated.
Fig. 4. Inhibition of suramin-activated PKCW by the PKC inhibitors
Goº 6976 and Goº 6983. Phosphorylation of syntide 2 by suramin-
(100 WM) activated PKCW was performed as described in Fig. 1.
However, Goº 6976 or Goº 6983 were added at the indicated concen-
trations. Values are the means ( þ S.E.) of two independent experi-
ments.
Fig. 5. E¡ect of suramin on PS/TPA-activated cPKC, PKCN, and
PKCW and on CS-activated PKCj. Phosphorylation of syntide 2 by
the various PKCs was performed as described in Fig. 1. However,
10 Wg of PS and 100 nM TPA were added to the assay for cPKC,
PKCN, and PKCW, and 1 Wg CS was added for PKCj. Data are
presented as per cent of control, i.e. the values determined in the
absence of suramin (100%). Values are the means ( þ S.E.) of two
independent experiments.
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investigation of PKC activities in vitro and possibly also in
vivo.
Whether this di¡erential action of suramin on the activity
of PKC isoforms plays a role in some of its biological e¡ects,
such as the suppression of proliferation, angiogenesis, and
tumor development [1,9,10] is presently under investigation.
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